• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

68Ga-FAPI 和 18F-FDG PET/CT 在会阴部乳腺外派杰病中的应用。

68Ga-FAPI and 18F-FDG PET/CT in Perineum Extramammary Paget Disease.

机构信息

From the Department of Nuclear Medicine, Fudan University Shanghai Cancer Center; Center for Biomedical Imaging, Fudan University; and Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.

出版信息

Clin Nucl Med. 2021 Apr 1;46(4):342-344. doi: 10.1097/RLU.0000000000003523.

DOI:10.1097/RLU.0000000000003523
PMID:33577199
Abstract

Extramammary Paget disease is a rare skin intraepithelial adenocarcinoma. Our case presents 68Ga-fibroblast activation protein inhibitor and 18F-FDG PET/CT imaging in a patient with perineum extramammary Paget disease. Compared with 18F-FDG PET/CT, the primary tumor, enlarged pelvic lymph nodes and right maxillofacial lesion showed higher uptake in 68Ga-fibroblast activation protein inhibitor PET/CT.

摘要

外阴派杰病是一种罕见的皮肤上皮内腺癌。我们的病例报告了一例会阴外阴派杰病患者的 68Ga-成纤维细胞激活蛋白抑制剂和 18F-FDG PET/CT 成像。与 18F-FDG PET/CT 相比,68Ga-成纤维细胞激活蛋白抑制剂 PET/CT 显示原发肿瘤、增大的盆腔淋巴结和右侧颌面病变摄取更高。

相似文献

1
68Ga-FAPI and 18F-FDG PET/CT in Perineum Extramammary Paget Disease.68Ga-FAPI 和 18F-FDG PET/CT 在会阴部乳腺外派杰病中的应用。
Clin Nucl Med. 2021 Apr 1;46(4):342-344. doi: 10.1097/RLU.0000000000003523.
2
Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.68Ga-DOTA-FAPI-04 PET/CT 肿瘤成像:与 18F-FDG PET/CT 在 22 种不同癌症类型中的比较。
Clin Nucl Med. 2022 Apr 1;47(4):e333-e339. doi: 10.1097/RLU.0000000000004073.
3
Extensive invasive extramammary Paget disease evaluated by F-18 FDG PET/CT: a case report.F-18 FDG PET/CT评估广泛侵袭性乳腺外佩吉特病:一例报告
Medicine (Baltimore). 2015 Jan;94(3):e371. doi: 10.1097/MD.0000000000000371.
4
18F-FDG PET/CT in Metastatic Extramammary Paget's Disease.18F-FDG PET/CT 于转移性外阴 Paget 病中的应用。
Clin Nucl Med. 2019 Oct;44(10):808-809. doi: 10.1097/RLU.0000000000002739.
5
The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.[68Ga]Ga-FAPI-04 PET/CT在[18F]FDG检查结果为阴性或不明确的原发灶不明患者中的额外作用。
Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1442-1452. doi: 10.1007/s00259-022-06095-y. Epub 2023 Jan 7.
6
Metastatic Extramammary Paget Disease of the Perianal Region.肛门周围转移性外阴派杰氏病。
Clin Nucl Med. 2019 Jul;44(7):e431-e432. doi: 10.1097/RLU.0000000000002619.
7
Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Gastric Kaposi Sarcoma.18F-FDG与68Ga-FAPI PET/CT在胃卡波西肉瘤中的比较
Clin Nucl Med. 2022 Sep 1;47(9):e596-e599. doi: 10.1097/RLU.0000000000004172. Epub 2022 Apr 5.
8
68Ga-FAPI PET/CT Detected Non-FDG-Avid Gastric Stromal Tumor.68Ga-FAPI PET/CT 检测到非 FDG 摄取的胃间质瘤。
Clin Nucl Med. 2022 Mar 1;47(3):226-227. doi: 10.1097/RLU.0000000000003856.
9
68Ga-FAPI-04 PET/CT Versus 18F-FDG PET/CT in Malignant Peritoneal Mesothelioma.68Ga-FAPI-04 PET/CT 与 18F-FDG PET/CT 在恶性腹膜间皮瘤中的应用比较。
Clin Nucl Med. 2022 Feb 1;47(2):e113-e115. doi: 10.1097/RLU.0000000000003858.
10
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in Dermatofibrosarcoma Protuberans.68Ga-FAPI 与 18F-FDG PET/CT 在隆突性皮肤纤维肉瘤中的比较。
Clin Nucl Med. 2022 Jul 1;47(7):629-631. doi: 10.1097/RLU.0000000000004212. Epub 2022 Apr 22.

引用本文的文献

1
Perianal Pagets disease complicated with lung adenocarcinoma and anal canal carcinoma: A case report and literature review.肛周派杰氏病并发肺腺癌和肛管癌 1 例报告并文献复习
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Aug 28;48(8):1274-1280. doi: 10.11817/j.issn.1672-7347.2023.220617.
2
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.基于成纤维细胞激活蛋白抑制剂的放射性药物的临床总结:癌症及其他。
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2844-2868. doi: 10.1007/s00259-022-05706-y. Epub 2022 Jan 31.